Abstract
We used Surveillance, Epidemiology, and End ResultsMedicare data (2000-2006) to describe treatment and survival in women diagnosed with metastatic breast cancer (MBC) who received trastuzumab. There were 610 patients with a mean age of 74 years. Overall, 32% received trastuzumab alone and 47% received trastuzumab plus a taxane. In multivariate analysis, trastuzumab plus chemotherapy was associated with a lower adjusted cancer mortality rate (Hazard Ratio [HRé 0.54; 95% Confidence Interval [CIé 0.39-0.74; p < .001) than trastuzumab alone among patients who received trastuzumab as part of first-line therapy. Adding chemotherapy to first-line trastuzumab for metastatic breast cancer is associated with improved cancer survival.
Original language | English (US) |
---|---|
Pages (from-to) | 573-584 |
Number of pages | 12 |
Journal | Cancer Investigation |
Volume | 29 |
Issue number | 9 |
DOIs | |
State | Published - Nov 2011 |
Externally published | Yes |
Keywords
- Breast cancers
- Chemotherapy
- Outcomes research
ASJC Scopus subject areas
- Oncology
- Cancer Research